<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448552</url>
  </required_header>
  <id_info>
    <org_study_id>20030243</org_study_id>
    <secondary_id>SCCC-2003050</secondary_id>
    <secondary_id>WIRB-20060071</secondary_id>
    <nct_id>NCT00448552</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer</brief_title>
  <official_title>Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving oxaliplatin together with&#xD;
      capecitabine works in treating patients with relapsed or metastatic head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with chemotherapy naïve relapsed or&#xD;
           metastatic head and neck cancer treated with oxaliplatin and capecitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the safety and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the one-year survival and overall survival of these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice&#xD;
      daily on days 2-15. Treatment repeats every 21 days for up to 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (complete response and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCI CTC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed head and neck cancer&#xD;
&#xD;
               -  Relapsed or metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No CNS metastases (unless CNS metastases have been stable for &gt; 3 months)&#xD;
&#xD;
          -  No clinically significant pericardial effusion&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute granulocyte count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times ULN (5 times ULN if liver metastases are present or&#xD;
             10 times ULN if bone disease is present)&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No clinically serious, uncontrolled cardiovascular disease&#xD;
&#xD;
          -  No New York Heart Association class III-IV heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No arrhythmia&#xD;
&#xD;
          -  No concurrent serious, uncontrolled infections&#xD;
&#xD;
          -  No other cancer requiring treatment within the past 5 years, except cured nonmelanoma&#xD;
             skin cancer or treated in situ cervical cancer&#xD;
&#xD;
          -  No loss of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome&#xD;
&#xD;
          -  No history of persistent neurosensory disorder including, but not limited to,&#xD;
             peripheral neuropathy&#xD;
&#xD;
          -  No history of uncontrolled seizures or CNS disorders&#xD;
&#xD;
          -  No history of psychiatric disability or other serious uncontrolled medical condition&#xD;
             that would preclude study compliance&#xD;
&#xD;
          -  No history of clinically significant interstitial lung disease and/or pulmonary&#xD;
             fibrosis&#xD;
&#xD;
          -  No prior hypersensitivity or unanticipated severe reaction to fluoropyrimidine&#xD;
             therapy, fluorouracil, or platinum-based compounds&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic or relapsed disease&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior participation in any investigational drug study&#xD;
&#xD;
          -  At least 6 months since prior adjuvant fluoropyrimidine therapy&#xD;
&#xD;
               -  No other prior fluoropyrimidines&#xD;
&#xD;
          -  At least 6 months since prior adjuvant platinum-based therapy&#xD;
&#xD;
               -  No other prior platinum-based therapy&#xD;
&#xD;
          -  No concurrent radiotherapy to the head and neck&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis E. Raez, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

